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Growing evidence indicates important roles for as-
trocytes in neurodevelopment and diseases. How-
ever, astrocytes and their roles in these processes
remain poorly understood. Despite recent progress
in reprogramming somatic cells into different types
of neural cells, reprogramming to astrocytes has
lagged. Here, we show that functional astrocytes
can be generated from mammalian fibroblasts us-
ing only small molecules. Induced mouse astro-
cytes resemble primary astrocytes in astrocytic
gene expression and epigenomic status and exhibit
functional properties in promoting neuronal matu-
ration, glutamate uptake, and calcium signaling.
Moreover, these cells can recapitulate the Alexander
disease phenotype of protein aggregation when
expressing Gfap with a disease-causing mutation.
The same compounds can also reprogram human
fibroblasts into astroglial progenitor cells that can
further mature into functional astrocytes. These
chemically induced astrocytes may provide cellular
models to uncover roles of astrocytes in normal neu-
rodevelopment and pathogenesis of neurological
diseases.INTRODUCTION
Astrocytes are glial cells that are located in all regions of the brain
(Molofsky et al., 2012; Verkhratsky et al., 2012). They have long
been held as the supporting components in neural tissues
(Wang and Bordey, 2008; Sofroniew and Vinters, 2010). How-
ever, over thepast decades, increasing evidence has established
a variety of essential functions for astrocytes in neural develop-
ment and in the pathogenesis of neurological diseases (Verkhrat-
sky et al., 2012). Astrocytes play a critical role in neuronal
maturation, synapse formation and plasticity, and glutamate
clearance to reduce excitotoxicity (Banker, 1980; Song et al.,
2002; Hama et al., 2004; Eroglu and Barres, 2010). Astrocyte
dysfunction contributes to many neurodegenerative diseasesThis is an open access article undand is the direct cause for some neurological disorders (Molofsky
et al., 2012; Verkhratsky et al., 2012), such as Alexander disease
(AxD) (Messing et al., 2012). Despite increasing data revealing
new roles for astrocytes, our knowledge on astrocytes remains
largely behind what we know about their neuronal counterpart.
There is an urgent need to establish newcellularmodels for astro-
cytes to uncover their versatile roles in the nervous system.
Expression of lineage-specific factors has been shown to
induce cell fate change, including reprogramming somatic cells
to induced pluripotent stem cells (iPSCs) (Takahashi and Yama-
naka, 2006) and converting one type of somatic cells to another
(Davis et al., 1987). The latter is also called direct reprogramming
or conversion. Extensive efforts have been devoted into convert-
ing somatic cells, like fibroblasts, into different types of neural
cells, such as neural stem cells (Kim et al., 2011; Han et al.,
2012; Lujan et al., 2012), neurons (Vierbuchen et al., 2010;
Caiazzo et al., 2011; Pang et al., 2011; Yoo et al., 2011), and ol-
igodendrocytes (Najm et al., 2013; Yang et al., 2013). However,
direct reprogramming of somatic cells into astrocytes has just
begun (Caiazzo et al., 2015).
Introducing exogenous factors in reprogramming has raised
various concerns, including the risk of insertional mutagenesis
and genetic alteration associated with retroviral delivery (Haw-
ley, 2008) and low reprogramming efficiency associated with
episomal transfection (Okita et al., 2008). During the course of
this study, cocktails of small molecules were shown to convert
mouse or human fibroblasts into neurons (Hu et al., 2015; Li
et al., 2015). However, no chemical reprogramming has been
reported to change fibroblasts, or any other mature cell types,
to astrocytes yet. Here, we demonstrate that small molecules
can be used to directly convert fibroblasts into functional astro-
cytes without transgenes.RESULTS
A Compound Cocktail Induces the Conversion from
MEFs to Astrocyte-like Cells
During our search for small molecules that can reprogram so-
matic cells into iPSCs, a chemical cocktail VC6TFZ was used
to reprogram mouse embryonic fibroblasts (MEFs) into iPSCs
(Hou et al., 2013). This compound combination includes the
histone deacetylase inhibitor VPA (V), the GSK3b inhibitorCell Reports 16, 781–792, July 19, 2016 ª 2016 The Author(s). 781
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Figure 1. Direct Reprogramming MEF into
Astrocyte-like Cells by VC6TO
(A) The scheme of MEF preparation is shown.
(B) The scheme of astrocytic reprogramming
with compound treatment. AM, astrocytemedium;
iAM, induced astrocyte medium; MEFM, MEF
medium.
(C) Immunostaining for GFAP and S100b in cells
derived from MEFs treated with DMSO or VC6TO
for 25 days. Nuclei were counter-stained with
DAPI. The scale bar represents 100 mm.
(D and E) The percentage of GFAP-positive cells
and GFAP and S100b double-positive cells from
total cells is shown. n = 3,000–4,000 cells.
See also Figure S1. For all quantifications in Fig-
ures 1, 2, 3, 4, 5, 6, and 7, error bars are SD of the
mean; *p < 0.05; **p < 0.01; ***p < 0.001.CHIR99021 (C), the TGFb inhibitor 616452 (6), the lysine specific
histone demethylase LSD1 inhibitor tranylcypromine (T), the
cyclic AMP inducer forskolin (F), and a histone methylation inhib-
itor DZNep (Z). In this chemical cocktail, compounds F and Z
were used together to induce the expression of Oct4, a factor
critical for reprogramming. We have previously identified
the small molecule OAC1 as an Oct4-activating compound
(Li et al., 2012). In this study, we tested whether the combi-
nation of VC6T with the OAC1 compound (together termed
VC6TO) could reprogram MEFs into iPSCs. MEFs were derived
from mice harboring an Oct4 promoter-driven GFP (OG2) re-
porter. Treatment with VC6TO for up to 25 days failed to induce
any Oct4-GFP-positive iPSC colonies from the OG2 MEFs.
Instead, we observed cells with astrocyte-like morphology
(Figure S1A).
This observation triggered us to test whether the VC6TO cock-
tail could reprogram MEFs into astrocytes. We paid special
attention to exclude any neural tissues from theMEF preparation
(Figure 1A) as described (Vierbuchen et al., 2010). Immuno-
staining MEFs with various neural lineage markers revealed no
contamination of neural progenitor cells, neurons, astrocytes,
and oligodendrocyte progenitor cells (Figure S1B); instead,
99.6% of cells expressed the fibroblast marker FSP1 (Fig-
ure S1C). These MEFs were treated with VC6TO and cultured
in induced astrocyte medium (iAM) (Figure 1B). Twenty-five
days after compound treatment, we immunostained the resul-
tant cells for astrocyte markers, glial fibrillary acidic protein
(GFAP) and S100b. We detected 12% GFAP-positive cells with
typical astrocyte morphology (Figures 1C and 1D). The percent-
age of GFAP+S100b+ cells was similar to that of GFAP+ cells
(Figure 1E). Together, these results indicate that the VC6TO782 Cell Reports 16, 781–792, July 19, 2016compounds can reprogram MEFs into
GFAP-positive and S100b-positive astro-
cyte-like cells.
A TGFb Inhibitor Is Critical for
Astrocytic Conversion
Next, we sought to identify compounds
critical for astrocytic conversion. The
combination of VC6, V6, or 6 alone wasable to induce GFAP-positive cells from MEFs, although the ef-
ficiency of conversion decreased when the number of com-
pounds was reduced. In contrast, subtraction of compound 6
from VC6TO led to failure of astrocytic conversion, as revealed
by the lack of GFAP-positive cells (Figures 2A and 2B). These
results suggest that compound 6 is necessary and sufficient to
induce the conversion of MEFs into astrocyte-like cells.
Because compound 6 is a transforming growth factor b (TGFb)
receptor 1 kinase inhibitor (Gellibert et al., 2004), we asked
whether other inhibitors of TGFb receptor 1 could induce astro-
cytic reprogramming together with VCTO.We tested A-83-01 (A)
or SB-431542 (S), two well-characterized inhibitors of TGFb re-
ceptor 1 (Inman et al., 2002; Tojo et al., 2005). Treating MEFs
with either the combination of VCTO with A (VCATO) or VCTO
with S (VCSTO) induced a substantial increase in GFAP-positive
cells with astrocyte morphology (Figures 2C and 2D). In contrast,
VCTO did not induce any GFAP-positive cells (Figures 2C and
2D). We noticed that VCATO and VCSTO induced more GFAP-
positive cells than the initial VC6TO combination (Figures 2B–
2D), with the highest conversion efficiency observed with
VCSTO, which induced 38% GFAP-positive cells at day 25 after
compound treatment. We therefore focused the rest of the study
on VCSTO-induced reprogramming.
We subtracted individual compounds from VCSTO to deter-
mine the effect of individual compounds on astrocytic conver-
sion. Similar to removal of 6, subtraction of S from VCSTO led
to almost complete loss of GFAP-positive cells (Figures 2E and
2F). Subtraction of T or C decreased reprogramming efficiency
dramatically, whereas removal of V or O reduced the efficiency
mildly (Figures 2E and 2F). On the other hand, compound S by
itself was sufficient to induce GFAP-positive cells from MEFs
Figure 2. A TGFb Inhibitor Is Critical for
Astrocytic Reprogramming
(A, C, E, and G) Immunostaining for GFAP in cells
derived from MEFs treated with DMSO control or
different compound combinations for 25 days.
Nuclei were counter-stained with DAPI. The scale
bar represents 100 mm.
(B, D, F, and H) The percentage of GFAP-positive
cells in MEFs treated with individual compound
combinations described in (A), (C), (E), and (G).
n = 2,000–6,000 cells.
See also Figures S2 and S3.(Figures 2G and 2H). Combination with C and T led to a more-
robust induction of GFAP-positive cells (Figures 2G and 2H).
These results indicate that compound S is critical for astrocytic
reprogramming, whereas compounds C and T promote reprog-
ramming efficiency.
Having identified S as a critical compound for astrocytic
reprogramming, next we determined the dose response of
compound S. We treated MEFs with VCSTO at different concen-
trations of S from 0 to 10 mMand observed increasedGFAP-pos-
itive cells with elevated concentrations of S (Figures S2A and
S2B). No toxicity was observed in cells treated with VCSTO at
the concentration of S at 10 mM or even higher (20 or 30 mM; Fig-
ure S2C). Because S is an inhibitor of TGFb receptor 1 (InmanCet al., 2002), we asked whether the
TGFb signaling is suppressed by VCSTO
treatment. After 24-hr VCSTO treat-
ment of MEFs, dramatic inhibition of
gene expression was observed for a
set of TGFb downstream effectors (Fig-
ure S2D), including Atf4, Col1a1, decorin
(Dcn), Gadd45b, Ifrd1, p21, p27, Tgfb1i1,
Tgfbi, and Tsc22d1, consistent with the
role of S in inhibiting TGFb signaling.
These results indicate that a TGFb inhibi-
tor is critical for converting fibroblasts
into astrocyte-like cells.
To determine whether astrocyte-like
cells could also be converted from other
cell types, we treatedmouse tail-tip fibro-
blasts (TTFs) with VCSTO compounds.
Twenty-five days after VCSTO treat-
ment, GFAP-positive and S100b-positive
cells with astrocyte morphology were
detected (Figure S3A). The percentage
of GFAP+S100b+ cells was similar to
that of GFAP+ cells (Figures S3A–S3C).
VCSTO-Induced Cells Express
Astrocytic Genes and Exhibit
Epigenetic Reprogramming
To verify that the VCSTO-reprogrammed
cells were indeed astrocytes, we first
determined astrocytic marker expression
in these cells. Double staining for GFAPand S100b revealed that the VCSTO-induced cells expressed
both GFAP and S100b (Figure 3A). In addition to GFAP and
S100b, ALDH1L1 has been identified to be a reliable marker for
astrocytes (Barres, 2008). Double staining the VCSTO-reprog-
rammed cells with GFAP and ALDH1L1 revealed that the com-
pound-induced cells were positive for both of these astrocytic
markers (Figure 3B). These results further confirmed the astro-
cyte identity of the VCSTO-induced cells.
Because astrocytes could be visualized by GFP fluores-
cence in the GFAP-GFP reporter mice (Zhuo et al., 1997),
we derived MEFs from these mice and treated them with
VCSTO to monitor astrocytic conversion. GFAP-GFP-positive
cells emerged around days 10–15 after VCSTO treatment. Theell Reports 16, 781–792, July 19, 2016 783
Figure 3. Expression of Astrocytic Markers
from VCSTO-Induced Cells
(A–C) Immunostaining for GFAP and S100b (A),
GFAP and ALDH1L1 (B), and GFAP and visualizing
GFAP-GFP (C) in VCSTO-induced cells. Nuclei
DAPI staining (blue) is included in the merged im-
ages. The scale bar represents 50 mm. In (C), MEFs
from GFAP-GFP mice were induced by VCSTO.
(D) The expression of astrocyte-related genes
in VCSTO-iAs, relative to MEF, measured by real-
time PCR. The expression in MEF was defined
as 1. n = 3 experimental repeats.
(E) Bisulfite sequencing the Gfap promoter region
in MEFs, iAs, and mouse pAs. Open and closed
circles indicate unmethylated and methylated
CpGs, respectively.
(F) Immunostaining for GFAP in cells treated with
VCSTO for 10, 15, 20, and 25 days. The scale bar
represents 100 mm.
(G) The percentage of GFAP-positive cells in cells
treated with VCSTO for different days.
(H) Real-time PCRof astrocytemarkers at different
days of VCSTO treatment. The expression at day 0
was defined as 1. n = 3 experimental repeats.
(I) RT-PCR of pluripotency markers, Oct4 and
Nanog, and neural progenitor markers, Sox1 and
Pax6, during the time course of VCSTO treatment.
RNA frommouse embryonic stem cells (ESCs) and
neural progenitor cells (NPCs) was included as
positive controls.induced cells were visualized for GFAP-GFP fluorescence and
immunostained for GFAP at day 25 after VCSTO treatment.
Nearly all GFAP-GFP positive cells were also positive for GFAP
immunostaining (Figure 3C).
Astrocytes express high levels of glutamate transporters, pre-
dominantly GLT-1 andGLAST (Chaudhry et al., 1995). Aquaporin
4 (AQP4), a member of the aquaporin family of membrane pro-
teins, is also enriched in astrocytes (Simard and Nedergaard,
2004). Real-time PCR revealed that the VCSTO-reprogrammed
cells expressed high levels of Glt-1, Glast, and Aqp4, in addition
to the astrocytic markers Gfap, S100b, and Aldh1l1 (Figure 3D),
further strengthening our conclusion that the VCSTO-reprog-
rammed cells are astrocytes.
An important aspect of reprogramming is epigenetic reprog-
ramming. Demethylation of the Gfap promoter has been shown
to be associated with astrocyte differentiation (Hatada et al.,784 Cell Reports 16, 781–792, July 19, 20162008). We tested whether the Gfap pro-
moter is demethylated during astrocytic
conversion from MEFs. VCSTO-induced
cells were sorted for GFAP-positive cells
after GFAP staining. The resultant cells
were subjected to DNA methylation
analysis. Bisulfite sequencing revealed
that the Gfap promoter of VCSTO-
induced cells was largely demethylated,
similar to that in primary astrocytes
(pAs) (Figure 3E), whereas the Gfap pro-
moter in parental MEFs was highly
methylated (Figure 3E). This result indi-cates that epigenetic reprogramming occurred during VCSTO-
induced astrocytic conversion.
To determine the dynamic expression pattern of astrocytic
genes during the conversion, we treated MEFs with VCSTO for
various time periods and performed immunostaining and RT-
PCR at days 10, 15, 20, and 25. We could see GFAP-positive
cells at day 10 after compound treatment, although the efficiency
was low (Figures 3F and 3G). By day 15, we detected more
than 15% GFAP-positive cells. The rate of conversion further
increased with time. By day 25, GFAP-positive cells reached
more than 30% (Figures 3F and 3G). In parallel RT-PCR analysis,
we observed increased expression of the astrocytic markers
Gfap, S100b, and Aldh1l1 along the time course, with the highest
induction at day 25 (Figure 3H). In contrast, we did not observe
the induction of the pluripotency genes Oct4 and Nanog, and
the neural progenitor genes Sox1 and Pax6, during the same
Figure 4. Genomic-wide Transcriptional
Profiling of VCSTO-iAs
(A) Heatmap presentation of microarray analysis of
MEFs, VCSTO-iAs, and mouse pAs. Genes upre-
gulated in iAs and pAs, compared to MEFs, are
shown in red, whereas genes downregulated in iAs
and pAs, compared to MEFs, are shown in blue.
(B) GO terms for genes upregulated in both iAs and
pAs, relative to MEFs, are shown in red, whereas
GO terms associated with genes downregulated in
iAs and pAs are shown in blue. The x axis repre-
sents enrichment scores, with p value calculated
via Fisher’s exact test.
(C) Heatmap presentation of a selected set of
fibroblast-relatedgenes (the upper four genes) and
astrocyte-related genes (the lower four genes).
(D and E) Real-time PCR validation of the
expression of four fibroblast-associated genes
(D) and four astrocyte-associated genes (E). The
expression in MEFs was defined as 1. n = 3
experimental repeats.
(F) Schematic presentation of different regions of
the brain.
(G)Relative expressionof regional subtypemarkers
in iAsmeasuredby real-timePCR.DB, dorsal brain;
FB, forebrain;HB, hindbrain; VB, ventral brain. n = 3
experimental repeats.
See also Figure S4.time course (Figure 3I), suggesting that these compounds induce
astrocytic conversion without inducing iPSC or neural progenitor
cell intermediates.
Genome-wide Remodeling andRegional Specification in
VCSTO-Induced Astrocytes
Next, we performed genome-wide profiling to compare gene
expression pattern of VCSTO-induced astrocytes with that of
pAs and MEFs. MEFs were derived from GFAP-GFP reporter
mice and treated with VCSTO for 25 days. The reprogrammed
cells were sorted for GFAP-GFP-positive cells and subjected
to DNA microarray analysis, along with pAs and MEFs. A heat-
map depicting all probe sets that were differentially expressed
by at least 1.5-fold showed that the transcriptional programCcharacteristic of MEFs was globally re-
programmed toward that of astrocytic
lineage (Figure 4A). Hierarchical clus-
tering revealed that the overall gene
expression pattern in induced astrocytes
(iAs) is more similar to that in pAs than
to parent MEFs (Figures S4A and S4B).
Among the genes upregulated (R2-fold)
in pAs compared to MEFs, 53.9% were
also upregulated in iAs; among the genes
downregulated in pAs relative to MEFs,
68.3% were also downregulated in iAs.
Genes upregulated in both iAs and pAs,
compared to MEFs, were significantly
enriched for gene ontology (GO) terms
associated with membrane and synapse
(Figure 4B), consistent with the criticalrole of astrocytes in synaptogenesis (Hama et al., 2004; Eroglu
and Barres, 2010). In contrast, genes downregulated in both
iAs and pAs, compared to MEFs, were significantly enriched
for GO terms linked to cell cycle and cell division (Figure 4B).
Validation of differentially expressed genes revealed that the
known fibroblast-related genes were downregulated in both
VCSTO-iAs and pAs, compared to MEFs (Figures 4C, 4D, and
S4C). In contrast, genes that are known to be expressed in astro-
cytes or involved in astrocyte differentiation and functions were
strongly upregulated in both iAs and pAs, compared to MEFs
(Figures 4C, 4E, and S4D). These results indicate that iAs
resemble pAs in genome-wide gene expression profile.
To determine the regional subtypes of VCSTO-iAs, we per-
formed real-time PCR to measure the expression levels ofell Reports 16, 781–792, July 19, 2016 785
Figure 5. Compound-iAs Are Functional
(A) Immunostaining mouse primary cortical neu-
rons for Map2 and synapsin after co-culturing with
MEF, iAs, andmouse pAs for 5 days. The scale bar
represents 50 mm.
(B) Quantification of Map2+ neurite length in
neurons co-cultured with MEFs, iAs, and pAs.
n = 1,000 cells.
(C) Increased Map2+synapsin+ puncta in neurons
co-cultured with iAs and pAs, relative to co-culture
with MEFs. The scale bar represents 10 mm.
(D) Quantification of Map2+synapsin+ puncta per
50-mm neurite length in neurons co-cultured with
MEFs, iAs, and pAs. n = 30 neurites.
(E) Measurement of glutamate uptake in iAs, pAs,
and MEFs. n = 3 experimental repeats.
(F) Calcium signal change in response to gluta-
mate stimulation is shown by calcium reporter
fluorescent dye intensity change (DF/F0) over time
(seconds) in iAs. The scale bar represents 100 mm.
(G) Lack of calcium spikes after glutamate stimu-
lation in MEFs.
(H) Calcium spikes after glutamate stimulation
in pAs.
(I) Quantification of DF/F0 in MEFs, iAs, and pAs in
response to glutamate stimulation. n = 400–600
cells.
See also Figure S5.markers for forebrain (Foxg1, Otx1, and Otx2), hindbrain (Hoxb4,
Egr2, and Grx2), dorsal (Pax3 and Trhr) and ventral (Nkx2.1 and
Lix1) brains (Figures 4F and S4E). iAs expressed both the fore-
brain markers Foxg1, Otx1, and Otx2 and the hindbrain markers
Hoxb4, Egr2, and Grx2, although the expression of the hindbrain
markers ismore robust (Figures 4G and S4E), suggesting that iAs
contain both anterior and posterior astrocyte subtypes, perhaps
with a more-abundant subpopulation of posterior astrocytes.
As for the dorsal-ventral regionality, VCSTO-iAs are predomi-
nantly dorsal, exhibiting robust Pax3 and Trhr expression but786 Cell Reports 16, 781–792, July 19, 2016barely detectable Nkx2.1 and Lix1
expression (Figures 4G and S4E). These
results indicate that the chemical iAs
can be regionally specified.
VCSTO-iAs Are Functional
To test whether VCSTO-iAs possess
astrocyte function to promote neuronal
maturation and synaptic formation, we
co-cultured them with mouse primary
cortical neurons. Neuronal maturation
was evaluated by immunostaining with
a mature neuronal marker, MAP2, at
day 5 after co-culture. Both total neu-
rite length and neurite complexity were
increased in neurons co-cultured with
iAs or pAs, compared to that in neurons
co-cultured with MEFs (Figures 5A, 5B,
and S5). Moreover, the density of synap-
sin-positive puncta along the MAP2-pos-
itive neurites was significantly increasedin neurons co-cultured with iAs and pAs, compared to
that in neurons co-cultured with MEFs (Figures 5C and 5D).
These results indicate that the VCSTO-iAs exhibit functional
property in promoting neuronal maturation and synaptogenesis,
like pAs.
Next, we determined whether the compound-iAs were func-
tional in glutamate uptake. pAs, iAs, and parental MEFs were
cultured in media containing glutamate for 6 hr; the concentra-
tion of glutamate in the media wasmeasured to determine gluta-
mate uptake. Both iAs and pAs exhibited substantial glutamate
Figure 6. VCSTO-iA Can Survive Transplantation and Be Used for
Disease Modeling
(A) Timeline of cell transplantation and brain harvest.
(B) GFP-labeled VCSTO- iAs in grafted brains that are positive for both GFP
and GFAP. The endogenous astrocytes are shown as GFP negative but GFAP
positive. The scale bar represents 25 mm.
(C) Higher-magnification images of individual GFP and GFAP double-posi-
tive cells. One (left) represents the cell indicated by arrow in (B); another
(right) represents a cell from a different region. The scale bar represents
10 mm.
(D) Transfection of the R239C AxD mutant GFAP-GFP to iAs induced GFAP
protein aggregates and aB-crystallin expression. iAs transfected with the WT
and AxD GFAP-GFP were immunostained for GFAP and aB-crystallin. The
transfected cells are indicated by GFP. Nuclei DAPI staining (blue) is included
in the merged images. The scale bars represent 10 mm.
(E) Ceftriaxone treatment reduced GFAP protein aggregates in iAs transfected
with the AxDmutantGFAP-GFP. iAs transfected with the AxDGFAP-GFPwereuptake, compared to MEFs (Figure 5E), indicating that com-
pound-iAs are functional in glutamate uptake.
Calcium imaging analysis revealed that the VCSTO-iAs ex-
hibited glutamate-induced calcium spikes, in a manner similar to
pAs, whereas MEFs did not respond to glutamate stimulation
with calcium spikes (Figures 5F–5I). These results suggest that
iAs acquire the ability to respond to neurotransmitters through cal-
cium signaling, like pAs. In summary, the chemical iAs are func-
tional astrocytes with the ability to promote neuronal survival and
maturation, uptake glutamate, and respond to calcium signaling.
VCSTO-iAs Can Survive and Retain Astrocyte Identity
In Vivo
To determine whether compound-iAs can survive and maintain
their astrocytic identity in vivo, we labeled the VCSTO-iAs with
a GFP reporter and transplanted them into the lateral ventricles
of immunodeficient neonatal non-obese diabetic (NOD) severe
combined immunodeficiency (SCID) gamma (NSG) mice (Fig-
ure 6A). Six weeks after transplantation, the grafted brains
were analyzed by immunostaining. The GFP-positive grafted
cells survived 6-week engraftment and continued to express
GFAP in the brain (Figures 6B and 6C). In contrast, the control
MEFs were not able to survive the engraftment in the trans-
planted brains (Figure S6A). These results indicate that the
VCSTO-iAs can survive engraftment and maintain astrocytic
marker expression in vivo.
Compound-iAs Can Be Used to Model Neurological
Disease
AxD is a neurological disease with astrocyte dysfunction and is
caused by genetic mutation of the GFAP gene (Messing et al.,
2012). Expression of AxD mutant GFAP induces the expression
of aB-crystallin, a small heat shock protein, and the formation
of protein aggregates containing GFAP and aB-crystallin in
astrocytes (Messing et al., 2012). We tested whether com-
pound-iAs could be used to model AxD. We transfected plasmid
expressing GFP fusion of the wild-type (WT) or AxD mutant
GFAP containing the R239C mutation, a hotspot mutation
for AxD (Hagemann et al., 2006), into VCSTO-iAs. Expression
of the AxD mutant GFAP in iAs promoted the expression of
aB-crystallin and the formation of protein aggregates immuno-
reactive for GFAP and aB-crystallin, whereas transfection of
the same amount of WT GFAP-GFP did not induce detectable
aB-crystallin expression and GFAP protein aggregation (Fig-
ure 6D). The b-lactam antibiotic ceftriaxone has been shown to
facilitate the elimination of AxDmutant GFAP protein aggregates
in pAs (Bachetti et al., 2010). We treated VCSTO-iAs transfected
with the AxDmutant GFAP with ceftriaxone. Substantial elimina-
tion of GFAP protein aggregates was detected in ceftriaxone-
treated cells, compared to vehicle-control-treated cells (Figures
6E and S6B). Although MEFs transduced with the AxD mutant
GFAP also exhibited GFAP protein aggregates, the fibro-
blast aggregates were not responsive to ceftriaxone treatment
(Figure S6C).treated with ceftriaxone (+Cef) or vehicle control (Cef) and stained for GFAP
and S100b. The scale bar represents 10 mm.
See also Figure S6.
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Figure 7. Reprogramming Human Fibro-
blasts into Astrocytic Cells by VCSTO
(A) Immunostaining for S100b in cells derived from
human fibroblasts (SCC058 for A–E) treated with
DMSO or VCSTO. Nuclei were counter-stained
with DAPI. The scale bar represents 100 mm for
(A) and (B).
(B) Immunostaining for S100b or GFAP in cells
derived from human fibroblasts treated with
DMSO or VCSTO, followed by CNTF treatment.
(C) The percentage of S100b-positive cells or
GFAP-positive cells is shown. n = 3,000–4,000
cells.
(D) Expression of astrocyte marker genes in
VCSTO-iAs as measured by real-time PCR. The
expression in human fibroblasts (hFs) was defined
as 1. n = 4 experimental repeats.
(E) Substantially elevated glutamate uptake in iAs
relative to parental fibroblasts (hFs). n = 3 experi-
mental repeats.
(F) Immunostaining for S100b and GFAP in cells
derived from human adult fibroblasts (AG14048 for
F–I) treated with DMSO or VCSTO. Nuclei were
counter-stained with DAPI. The scale bar repre-
sents 100 mm.
(G) The percentage of S100b-positive cells or
GFAP-positive cells is shown. n = 1,000 cells.
(H) Expression of astrocyte marker genes in iAs
relative to hFs as measured by real-time PCR.
n = 4 experimental repeats.
(I) Substantially elevated glutamate uptake in
human iAs relative to hFs. n = 3 experimental
repeats.
See also Figure S7.Moreover, glutamate uptake assay revealed that VCSTO-
iAs transduced with the AxD mutant GFAP exhibited reduced
glutamate uptake, compared to VCSTO-iAs transduced with
WT GFAP (Figure S6D). These results together suggest that
compound-iAs could be used to model neurological diseases
with astrocyte dysfunction and test candidate drugs for these
diseases.
VCSTOCould InduceAstrocytic Conversion fromHuman
Fibroblasts
To determine whether human fibroblasts could be induced
for astrocytic conversion using small-molecule compounds, we
treated human foreskin fibroblasts with VCSTO compounds.
Forty days after compound treatment, we observed a large num-
ber of cells with astroglial progenitor-like morphology. Because788 Cell Reports 16, 781–792, July 19, 2016S100b is a marker for human astroglial
progenitor cells and astrocytes, we
stained the VCSTO-treated cells for
S100b and found that more than 30% of
cells were S100b+ cells, whereas no
S100b+ cells were detected in DMSO-
treated cells (Figures 7A and 7C). Treat-
ment of the astroglial progenitor cells
with ciliary neurotrophic factor (CNTF)
for 6 days allowed thematuration of thesecells into astrocytes with bigger cell body and more-complex
morphology. Immunostaining of the resultant cells allowed the
detection of both S100b+ cells and GFAP+ cells in VCSTO-
treated cells (Figures 7B and 7C).
In a parallel experiment, we detected robust induction of astro-
cyte marker genes, GFAP, S100b, AQP4, and EAAT2, in VCSTO-
reprogrammed cells (iAs), to a level that is similar to or higher than
that in human iPSC-derived astrocytes (hA) (Figure 7D). In
contrast, the expression level of the astrocytic genes is much
lower in DMSO-treated human fibroblasts (hF) (Figure 7D). More-
over, human iAs exhibited potent glutamate uptake, compared to
parental fibroblasts (Figure 7E). Calcium imaging analysis re-
vealed that the human iAs exhibited glutamate-induced calcium
signal change, similar to hA, whereas parental fibroblasts did
not exhibit calcium signal change in response to glutamate
stimulation (Figure S7). These results together indicate that the
VCSTO cocktail could induce human fibroblasts into astroglial
progenitor cells that can be further matured into functional
astrocytes.
To determine whether adult human fibroblasts could be
induced into astrocytes using small molecules, we treated
human fibroblasts derived from a 71-year-old donor with the
VCSTO compounds. After 40 days of VCSTO compound treat-
ment and 10 days of CNTF-induced maturation, both S100b+
cells and GFAP+ cells were detected in VCSTO-treated cells,
but not in DMSO-treated cells (Figures 7F and 7G). RT-PCR anal-
ysis revealed potent induction of astrocyte marker genes, GFAP,
S100b, SLC1A2, and EAAT2 in VCSTO-induced cells, compared
to that in DMSO-treated cells (Figure 7H). The iAs also exhibited
substantial glutamate uptake, compared to parental fibroblasts
(Figure 7I). These results together indicate that the VCSTO com-
pounds could induce human adult fibroblasts into functional
astrocytes.
DISCUSSION
In this study, we reprogrammed mouse fibroblasts into func-
tional astrocytes, which possess the ability to promote neuronal
maturation and synaptic formation, uptake glutamate, and
induce calcium signal in response to glutamate stimulation.
Although rapid progress has been made in converting somatic
cells into other types of neural cells, such as neural stem cells,
neurons, and oligodendrocytes, direct reprogramming of so-
matic cells into astrocytes remains largely behind. Induced
neurons can be developed into useful tools for modeling a variety
of neurological diseases affecting neurons (Lujan et al., 2012).
However, induced neuronal cells would have limitations for
modeling disease affecting astrocytes. Although astrocytes
could be derived from iPSCs, the differentiation process is
lengthy. These limitations could be overcome by inducing astro-
cytes directly from fibroblasts in a relatively short period of time
as reported in this study.
In this study, we present an example of pure chemical induc-
tion of lineage conversion from a mature somatic cell type to as-
trocytes. A study reported the derivation of iPSCs from mouse
somatic cells using six small molecules VC6TFZ (Hou et al.,
2013). Part of this compound cocktail, VC6 was used to convert
somatic cells into neural progenitor cells under hypoxia (Cheng
et al., 2014). In recent studies, different combinations of small
molecules were used to convert somatic cells into neuronal cells
(Hu et al., 2015; Li et al., 2015; Zhang et al., 2015). In this study,
we directly reprogrammed mammalian fibroblasts into astro-
cytes using compounds only, without using any transgenes or
viral transduction. Moreover, we found that the TGFb inhibitor
6 or S alone was able to induce GFAP-positive cells from
MEFs, providing an example that one single compound is able
to induce the conversion of one somatic cell type to another.
Several possible reasons could explain why inhibition of TGFb
pathway could induce reprogramming of fibroblasts into astro-
cytes. First, TGFb is a cytokine for induction of epithelial-to-
mesenchymal transition. Inhibitionof TGFb signalingcould induce
reprogramming of fibroblasts by suppressing the fibroblast gene
expression program through a mesenchymal-to-epithelial con-version (Lin et al., 2009; Maherali and Hochedlinger, 2009). Sec-
ond, inhibition of TGFb signaling has been shown to promote neu-
roectoderm specification (Smith et al., 2008). Moreover, inhibition
of TGFb signaling can induce bone morphogenetic protein (BMP)
signaling (Xu et al., 2008; Ichida et al., 2009), which has been
shown to induceastrocytic differentiation and establish andmain-
tain astrocytic identity (Grosset al., 1996;RajanandMcKay,1998;
Bonaguidi et al., 2005; Kohyama et al., 2010).
Previous studies described ways to derive astrocytes from
somatic cells by going through iPSC or induced neural stem
cell (iNSC)/induced neural progenitor cell (iNPC) intermediates
(Han et al., 2012; Lujan et al., 2012; Ring et al., 2012; Thier
et al., 2012; Cassady et al., 2014). In these studies, astrocytes
were derived from MEFs at an efficiency of 0.004%–2% in up
to 70 days. Our method of direct reprogramming does not go
through iPSC or iNSC/iNPC intermediate state. Astrocytes could
be converted from MEFs at an efficiency of 38% in 20–25 days
in this study. Therefore, the direct chemical reprogramming
method described in this study provides a more rapid and effi-
cient way to derive astrocytes from fibroblasts.
Furthermore, this study provides proof of concept that chem-
ical iAs can be used to model diseases with astrocyte dysfunc-
tion. When we transfected an AxD mutant GFAP into iAs, we
were able to recapitulate the phenotype of GFAP protein aggre-
gation observed in AxD patient astrocytes. Moreover, these pro-
tein aggregates were responsive to ceftriaxone treatment. Our
knowledge about astrocytes is still very limited. The chemical
iAs developed in this study will provide a tool for us to study
neurodevelopment in glial context and to model a variety of
neurological diseases with astrocyte dysfunction. Generating
iAs containing disease-causing mutations will provide novel in-
sights into our understanding of astrocyte-associated diseases.
EXPERIMENTAL PROCEDURES
Cell Culture
MEFs and TTFs were derived from embryonic day 13.5 (E13.5) embryos of
Oct4-GFP transgenic (OG2; Szabo´ et al., 2002; kindly provided by Dr. Szabo),
WT, or GFAP-GFP transgenic mice (Jackson Laboratory; Zhuo et al., 1997).
These cells were cultured in MEFmedium containing DMEM, 10% fetal bovine
serum (FBS), 0.1mMnonessential amino acids, and 2mML-glutamine.Mouse
pAs were isolated from postnatal day 1 (P1)–2 pups following published proto-
col (Schildge et al., 2013) and cultured in DMEM containing 10% FBS.
Direct Reprogramming Mouse Fibroblasts into Astrocytes
MEFswereplatedon6-well or12-well platesatacelldensityof 33103cells/cm2.
Cells were cultured in MEF medium for 24 hr and then changed to mouse iAM
containing knockout DMEM with 10% knockout serum replacer, 10% FBS,
2mML-glutamine,0.1mMnon-essential aminoacids (NEAA),0.1mMb-mercap-
toethanol, and 100 ng/ml fibroblast growth factor (FGF). Cells were treated
with compounds, including 500 nM valproic acid (VPA) (Stemgent), 3 mM
CHIR99021 (D&CChemicals), 10mMSB-431542 (D&CChemicals), 10mMtranyl-
cypromine (Stemgent), and1mMOAC1 (Li et al., 2012) for 10days; re-platedonto
Matrigel-coated plates (BD Biosciences); and continued with compound treat-
ment for another 15 days. Cells were then switched tomouse astrocytemedium
(AM) containing DMEMwith 10% heat-inactivated FBS.
Immunocytochemistry
Cells were fixed in 4%paraformaldehyde (PFA) for 10min, followed by washes
in PBS at room temperature (RT). Cells were then blocked with 3% donkey
serum in PBS containing 0.01% Triton X-100 for 1 hr at RT, incubated withCell Reports 16, 781–792, July 19, 2016 789
primary antibodies overnight at 4C, and thenwashedwith PBS and incubated
with secondary antibodies for 1 hr at RT.We used primary antibodies for GFAP
(1:2,000; DAKO; Z0334), S100b (1:200; NOVUS; NB110-57478), ALDH1L1
(1:200; NeuroMab; 75-140), synapsin (1:1,000; SYSY; 106103), aB-crystallin
(1:200; Enzo; ADI-SPA-223), MAP2 (1:500; GeneTex; GTX11268), Tuj1
(1:6,000; Covance; PRB-435P), NeuN (1:400; Millipore; MAB377), Pax6
(1:500; Covance; PRB-278P), Sox1 (1:500; Millipore; AB15766), Oligo2
(1:200; GeneTex; GTX62440), NG2 (1:500; Millipore; MAB5384), and NKX2.2
(1:50; DSHB; 745A5). Nuclei were stained with DAPI (1:6,000; Sigma; D9564).
Cell Sorting and Microarray Gene Expression Analysis
GFAP-GFP-positive iAs were sorted using the FACSAria III cell sorter (BD
Bioscience). Gene expression profiling was performed using Mouse Gene
2.0 ST array (Affymetrix). Microarray data analysis was performed using Partek
Genomics Suite (Partek). Expression values were robust multi-array average
(RMA) normalized (Irizarry et al., 2003). Fold-change values represent the linear
ratio between signal intensities when the ratio value is greater than 1 and 1/
ratio when the ratio is less than 1. Genes were defined as differentially ex-
pressed if they showed a fold-change value >1.5. Heatmaps to visualize differ-
entially expressed genes were produced in Partek using Euclidian distance
for hierarchical clustering of standardized expression values. GO enrichment
was performed for functional enrichment of commonly affected genes, with
p values calculated via Fisher’s exact test.
Real-Time PCR
Total RNAwas extracted using Trizol reagent (QIAGEN); cDNAswere prepared
using Tetro cDNA synthesis kit (Bioline). Real-time PCR was performed using
DyNAmo Flash SYBR Green qPCR mix on a StepOnePlus system (Applied
Biosciences) and normalized to b-actin. Primers used are listed in Table S1.
Astrocyte-Neuron Co-cultures
Mouse cortical neurons were isolated from E13.5 mouse embryo and cultured
in neuronal culture media (neurobasal; 1X B27; 2 mM L-glutamine) alone or
directly on a layer of iAs, mouse pAs, or MEF for 5 days. Mouse neurons, iA,
pAs, or MEFs were plated at the same density of 10,000 cells/cm2. The co-
cultured cells were stained for MAP2 and synapsin. The synapsin + puncta
along the MAP2+ neurites were expressed as the number of puncta per
50-mm neurite length.
Transplantation
iAs labeled by GFP-expressing lentivirus were dissociated using trypsin-EDTA
and resuspended in medium at 100,000 cells/ml density and kept on ice. Two-
microliter cell suspensions were injected 1 mm from the midline between the
Bregma and Lambda and 1 mm deep into the anterior lateral ventricles of
immunodeficient neonatal NSG mice. After 6 weeks, mice were euthanized
and perfused with 4% PFA for 5 min. Brain tissues were harvested for immu-
nostaining. All animal work was performed under the Institutional Animal Care
and Use Committee (IACUC) protocol approved by the City of Hope IACUC
Committee.
Ca2+ Imaging
Cells were seeded in 12-well plates at a density of 1 3 105 cells per well and
stimulated with 10 mM glutamic acid. Fluo-4 Calcium Imaging Kit (Invitrogen
F10489) was used to monitor calcium waves following manufacturer’s instruc-
tions. Calcium waves were captured using a Zeiss Observer Microscope.
Wave intensity was analyzed using Image Pro Premier, and the intensity was
measured as DF/F0 = (F  F0)/F0.
Bisulfite Sequencing
Genomic DNAs were isolated from MEF, fluorescence-activated cell sorting
(FACS)-sorted iAs, and mouse pAs using a Genomic DNA Purification Kit
(QIAGEN). Bisulfite conversion of genomic DNAs was carried out using the
EZ DNA Methylation-Gold Kit (Zymo Research). The bisulfite-modified DNA
was then used as a template for PCR to amplify the promoter region of
Gfap. The amplified products were cloned into the pCR2.1-TOPO cloning vec-
tor (Invitrogen), and ten randomly selected clones were sequenced using T7 or
M13R primers.790 Cell Reports 16, 781–792, July 19, 2016Glutamate Uptake Assay
The glutamate uptake was measured using the Glutamate Assay Kit
(BioVision). iAs were plated at a concentration of 2 3 104 cells per well
in a 24-well plate. One hundred micromolar L-glutamate was added to
each well. After incubation for 6 hr, the glutamate concentration in the
media was measured and presented as nmol of glutamate per mg of total
proteins.
Transfection into iAs
iAs were seeded at 13 105 cells per well in 12-well plates and incubated over-
night. Then, 2 mg plasmid of human WT GFAP-GFP or AxD mutant GFAP-GFP
with the R239C mutation (Bachetti et al., 2008) was transfected into iAs using
Lipofectamine 2000 (Invitrogen). Forty-eight hours after transfection, cells
were assayed by immunostaining. For drug treatment, 24 hr after transfection,
cells were treated with vehicle control or 100 mMceftriaxone for 48 hr, followed
by immunostaining.
Inducing Human Fibroblasts for Astrocytic Conversion
Human fibroblasts were purchased from Millipore (SCC058) or Coriell
(AG14048) and tested for lack of mycoplasm contamination. Human fibro-
blasts were seeded onto 6-well plates at the density of 104 cells/cm2 and
cultured in either FibroGRO complete medium (for SCC058) or Eagle’s min-
imum essential medium (MEM) with 15% non-inactivated FBS (for AG14048)
for 24 hr and then switched to iAM containing DMEM/F12 with 2 mM L-gluta-
mine, 0.1 mM NEAA, 13N2, 13B27, and 100 ng/ml FGF. For SCC058, cells
were treated with VCSTO compounds, including 500 nM VPA (Stemgent),
3 mM CHIR99021 (D&C Chemicals), 10 mM SB-431542 (D&C Chemicals),
10 mM tranylcypromine (Stemgent), and 1 mM OAC1 (Li et al., 2012)
for 20 days, re-plated onto Matrigel-coated plates, and continued with
compound treatment for another 20 days. Cells were then treated with
10 ng/ml CNTF for another 6 days. For AG14048, cells were treated
with VCSTO compounds at the same concentration as described above
for 30 days and then treated with VCSTO together with 10 ng/ml CNTF for
another 10 days.
Statistical Analysis
Independent-samples t test was used to compare means of two independent
samples. A value of p < 0.05 was considered statistically significant.
ACCESSION NUMBERS
The accession number for the microarray data reported in this paper is NCBI
GEO: GSE81927.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and one table and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.06.042.
AUTHOR CONTRIBUTIONS
E.T. and Y.S. conceived the study; E.T. and Y.S. designed research; E.T., Guo-
qiang Sun, Guihua Sun, J.C., and P.Y. performed research; E.T., Guoqiang
Sun, Guihua Sun, C.W., A.D.R., and Y.S. analyzed data; and Y.S. and E.T. pre-
pared the manuscript with input from all other authors.
ACKNOWLEDGMENTS
We thank Dr. I. Ceccherini from Istituto Giannina Gaslini, Italy for providing the
WT and AxD mutant GFAP-GFP plasmids; Q. Cui, L. Li, W. Li, and K. Murai for
critical reading of themanuscript; and Dr. L. Yang for help with microarray data
analysis and data deposit. Guoqiang Sun and J.C. are Herbert Horvitz Fellows.
This work was supported by the Sidell Kagan Foundation, California Institute
for Regenerative Medicine TR2-01832 and RB4-06277. Research reported
in this publication included work performed in the Analytical Cytometry and
Integrative Genomics Cores supported by the National Cancer Institute of the
NIH under award number P30CA33572. The content is solely the responsibility
of the authors and does not necessarily represent the official views of the NIH.
Received: December 30, 2015
Revised: April 7, 2016
Accepted: June 8, 2016
Published: July 7, 2016
REFERENCES
Bachetti, T., Caroli, F., Bocca, P., Prigione, I., Balbi, P., Biancheri, R., Filo-
camo, M., Mariotti, C., Pareyson, D., Ravazzolo, R., and Ceccherini, I.
(2008). Mild functional effects of a novel GFAP mutant allele identified in a fa-
milial case of adult-onset Alexander disease. Eur. J. Hum. Genet. 16, 462–470.
Bachetti, T., Di Zanni, E., Balbi, P., Bocca, P., Prigione, I., Deiana, G.A.,
Rezzani, A., Ceccherini, I., and Sechi, G. (2010). In vitro treatments with ceftri-
axone promote elimination ofmutant glial fibrillary acidic protein and transcrip-
tion down-regulation. Exp. Cell Res. 316, 2152–2165.
Banker, G.A. (1980). Trophic interactions between astroglial cells and hippo-
campal neurons in culture. Science 209, 809–810.
Barres, B.A. (2008). The mystery and magic of glia: a perspective on their roles
in health and disease. Neuron 60, 430–440.
Bonaguidi, M.A., McGuire, T., Hu, M., Kan, L., Samanta, J., and Kessler, J.A.
(2005). LIF and BMP signaling generate separate and discrete types of GFAP-
expressing cells. Development 132, 5503–5514.
Caiazzo, M., Dell’Anno, M.T., Dvoretskova, E., Lazarevic, D., Taverna, S., Leo,
D., Sotnikova, T.D., Menegon, A., Roncaglia, P., Colciago, G., et al. (2011).
Direct generation of functional dopaminergic neurons from mouse and human
fibroblasts. Nature 476, 224–227.
Caiazzo,M., Giannelli, S., Valente, P., Lignani, G., Carissimo, A., Sessa, A., Co-
lasante, G., Bartolomeo, R., Massimino, L., Ferroni, S., et al. (2015). Direct
conversion of fibroblasts into functional astrocytes by defined transcription
factors. Stem Cell Reports 4, 25–36.
Cassady, J.P., D’Alessio, A.C., Sarkar, S., Dani, V.S., Fan, Z.P., Ganz, K.,
Roessler, R., Sur, M., Young, R.A., and Jaenisch, R. (2014). Direct lineage con-
version of adult mouse liver cells and B lymphocytes to neural stem cells. Stem
Cell Reports 3, 948–956.
Chaudhry, F.A., Lehre, K.P., van Lookeren Campagne, M., Ottersen, O.P.,
Danbolt, N.C., and Storm-Mathisen, J. (1995). Glutamate transporters in glial
plasmamembranes: highly differentiated localizations revealed by quantitative
ultrastructural immunocytochemistry. Neuron 15, 711–720.
Cheng, L., Hu, W., Qiu, B., Zhao, J., Yu, Y., Guan,W., Wang, M., Yang, W., and
Pei, G. (2014). Generation of neural progenitor cells by chemical cocktails and
hypoxia. Cell Res. 24, 665–679.
Davis, R.L., Weintraub, H., and Lassar, A.B. (1987). Expression of a single
transfected cDNA converts fibroblasts to myoblasts. Cell 51, 987–1000.
Eroglu, C., and Barres, B.A. (2010). Regulation of synaptic connectivity by glia.
Nature 468, 223–231.
Gellibert, F., Woolven, J., Fouchet, M.H., Mathews, N., Goodland, H., Love-
grove, V., Laroze, A., Nguyen, V.L., Sautet, S., Wang, R., et al. (2004). Identifi-
cation of 1,5-naphthyridine derivatives as a novel series of potent and selective
TGF-beta type I receptor inhibitors. J. Med. Chem. 47, 4494–4506.
Gross, R.E., Mehler, M.F., Mabie, P.C., Zang, Z., Santschi, L., and Kessler, J.A.
(1996). Bone morphogenetic proteins promote astroglial lineage commitment
by mammalian subventricular zone progenitor cells. Neuron 17, 595–606.
Hagemann, T.L., Connor, J.X., and Messing, A. (2006). Alexander disease-
associated glial fibrillary acidic protein mutations in mice induce Rosenthal
fiber formation and a white matter stress response. J. Neurosci. 26, 11162–
11173.
Hama, H., Hara, C., Yamaguchi, K., and Miyawaki, A. (2004). PKC signaling
mediates global enhancement of excitatory synaptogenesis in neurons trig-
gered by local contact with astrocytes. Neuron 41, 405–415.Han, D.W., Tapia, N., Hermann, A., Hemmer, K., Ho¨ing, S., Arau´zo-Bravo,
M.J., Zaehres, H., Wu, G., Frank, S., Moritz, S., et al. (2012). Direct reprogram-
ming of fibroblasts into neural stem cells by defined factors. Cell Stem Cell 10,
465–472.
Hatada, I., Namihira, M., Morita, S., Kimura, M., Horii, T., and Nakashima, K.
(2008). Astrocyte-specific genes are generally demethylated in neural precur-
sor cells prior to astrocytic differentiation. PLoS ONE 3, e3189.
Hawley, R.G. (2008). Does retroviral insertional mutagenesis play a role in the
generation of induced pluripotent stem cells? Mol. Ther. 16, 1354–1355.
Hou, P., Li, Y., Zhang, X., Liu, C., Guan, J., Li, H., Zhao, T., Ye, J., Yang,W., Liu,
K., et al. (2013). Pluripotent stem cells induced from mouse somatic cells by
small-molecule compounds. Science 341, 651–654.
Hu, W., Qiu, B., Guan, W., Wang, Q., Wang, M., Li, W., Gao, L., Shen, L.,
Huang, Y., Xie, G., et al. (2015). Direct conversion of normal and Alzheimer’s
disease human fibroblasts into neuronal cells by small molecules. Cell Stem
Cell 17, 204–212.
Ichida, J.K., Blanchard, J., Lam, K., Son, E.Y., Chung, J.E., Egli, D., Loh, K.M.,
Carter, A.C., Di Giorgio, F.P., Koszka, K., et al. (2009). A small-molecule inhib-
itor of tgf-Beta signaling replaces sox2 in reprogramming by inducing nanog.
Cell Stem Cell 5, 491–503.
Inman, G.J., Nicola´s, F.J., Callahan, J.F., Harling, J.D., Gaster, L.M., Reith,
A.D., Laping, N.J., and Hill, C.S. (2002). SB-431542 is a potent and specific in-
hibitor of transforming growth factor-beta superfamily type I activin receptor-
like kinase (ALK) receptors ALK4, ALK5, and ALK7.Mol. Pharmacol. 62, 65–74.
Irizarry, R.A., Hobbs, B., Collin, F., Beazer-Barclay, Y.D., Antonellis, K.J.,
Scherf, U., and Speed, T.P. (2003). Exploration, normalization, and summaries
of high density oligonucleotide array probe level data. Biostatistics 4, 249–264.
Kim, J., Efe, J.A., Zhu, S., Talantova, M., Yuan, X., Wang, S., Lipton, S.A.,
Zhang, K., and Ding, S. (2011). Direct reprogramming of mouse fibroblasts
to neural progenitors. Proc. Natl. Acad. Sci. USA 108, 7838–7843.
Kohyama, J., Sanosaka, T., Tokunaga, A., Takatsuka, E., Tsujimura, K.,
Okano, H., and Nakashima, K. (2010). BMP-induced REST regulates
the establishment and maintenance of astrocytic identity. J. Cell Biol. 189,
159–170.
Li, W., Tian, E., Chen, Z.X., Sun, G., Ye, P., Yang, S., Lu, D., Xie, J., Ho, T.V.,
Tsark, W.M., et al. (2012). Identification of Oct4-activating compounds that
enhance reprogramming efficiency. Proc. Natl. Acad. Sci. USA 109, 20853–
20858.
Li, X., Zuo, X., Jing, J., Ma, Y., Wang, J., Liu, D., Zhu, J., Du, X., Xiong, L., Du,
Y., et al. (2015). Small-molecule-driven direct reprogramming of mouse fibro-
blasts into functional neurons. Cell Stem Cell 17, 195–203.
Lin, T., Ambasudhan, R., Yuan, X., Li, W., Hilcove, S., Abujarour, R., Lin, X.,
Hahm, H.S., Hao, E., Hayek, A., and Ding, S. (2009). A chemical platform for
improved induction of human iPSCs. Nat. Methods 6, 805–808.
Lujan, E., Chanda, S., Ahlenius, H., S€udhof, T.C., andWernig, M. (2012). Direct
conversion of mouse fibroblasts to self-renewing, tripotent neural precursor
cells. Proc. Natl. Acad. Sci. USA 109, 2527–2532.
Maherali, N., and Hochedlinger, K. (2009). Tgfbeta signal inhibition cooperates
in the induction of iPSCs and replaces Sox2 and cMyc. Curr. Biol. 19, 1718–
1723.
Messing, A., Brenner, M., Feany, M.B., Nedergaard, M., and Goldman, J.E.
(2012). Alexander disease. J. Neurosci. 32, 5017–5023.
Molofsky, A.V., Krencik, R., Ullian, E.M., Tsai, H.H., Deneen, B., Richardson,
W.D., Barres, B.A., and Rowitch, D.H. (2012). Astrocytes and disease: a neuro-
developmental perspective. Genes Dev. 26, 891–907.
Najm, F.J., Lager, A.M., Zaremba, A., Wyatt, K., Caprariello, A.V., Factor, D.C.,
Karl, R.T., Maeda, T., Miller, R.H., and Tesar, P.J. (2013). Transcription factor-
mediated reprogramming of fibroblasts to expandable, myelinogenic oligo-
dendrocyte progenitor cells. Nat. Biotechnol. 31, 426–433.
Okita, K., Nakagawa, M., Hyenjong, H., Ichisaka, T., and Yamanaka, S. (2008).
Generation of mouse induced pluripotent stem cells without viral vectors.
Science 322, 949–953.Cell Reports 16, 781–792, July 19, 2016 791
Pang, Z.P., Yang, N., Vierbuchen, T., Ostermeier, A., Fuentes, D.R., Yang,
T.Q., Citri, A., Sebastiano, V., Marro, S., S€udhof, T.C., and Wernig, M.
(2011). Induction of human neuronal cells by defined transcription factors.
Nature 476, 220–223.
Rajan, P., and McKay, R.D. (1998). Multiple routes to astrocytic differentiation
in the CNS. J. Neurosci. 18, 3620–3629.
Ring, K.L., Tong, L.M., Balestra, M.E., Javier, R., Andrews-Zwilling, Y., Li, G.,
Walker, D., Zhang, W.R., Kreitzer, A.C., and Huang, Y. (2012). Direct reprog-
ramming of mouse and human fibroblasts into multipotent neural stem cells
with a single factor. Cell Stem Cell 11, 100–109.
Schildge, S., Bohrer, C., Beck, K., and Schachtrup, C. (2013). Isolation and
culture of mouse cortical astrocytes. J. Vis. Exp., pii: 50079.
Simard, M., and Nedergaard, M. (2004). The neurobiology of glia in the context
of water and ion homeostasis. Neuroscience 129, 877–896.
Smith, J.R., Vallier, L., Lupo, G., Alexander, M., Harris, W.A., and Pedersen,
R.A. (2008). Inhibition of Activin/Nodal signaling promotes specification of
human embryonic stem cells into neuroectoderm. Dev. Biol. 313, 107–117.
Sofroniew, M.V., and Vinters, H.V. (2010). Astrocytes: biology and pathology.
Acta Neuropathol. 119, 7–35.
Song, H., Stevens, C.F., and Gage, F.H. (2002). Astroglia induce neurogenesis
from adult neural stem cells. Nature 417, 39–44.
Szabo´, P.E., H€ubner, K., Scho¨ler, H., and Mann, J.R. (2002). Allele-specific
expression of imprinted genes in mouse migratory primordial germ cells.
Mech. Dev. 115, 157–160.
Takahashi, K., and Yamanaka, S. (2006). Induction of pluripotent stem cells
from mouse embryonic and adult fibroblast cultures by defined factors. Cell
126, 663–676.
Thier, M., Wo¨rsdo¨rfer, P., Lakes, Y.B., Gorris, R., Herms, S., Opitz, T., Seiferl-
ing, D., Quandel, T., Hoffmann, P., No¨then, M.M., et al. (2012). Direct conver-
sion of fibroblasts into stably expandable neural stem cells. Cell Stem Cell 10,
473–479.792 Cell Reports 16, 781–792, July 19, 2016Tojo, M., Hamashima, Y., Hanyu, A., Kajimoto, T., Saitoh, M., Miyazono, K.,
Node, M., and Imamura, T. (2005). The ALK-5 inhibitor A-83-01 inhibits
Smad signaling and epithelial-to-mesenchymal transition by transforming
growth factor-beta. Cancer Sci. 96, 791–800.
Verkhratsky, A., Sofroniew, M.V., Messing, A., deLanerolle, N.C., Rempe, D.,
Rodrı´guez, J.J., and Nedergaard, M. (2012). Neurological diseases as primary
gliopathies: a reassessment of neurocentrism. ASN Neuro 4, e00082.
Vierbuchen, T., Ostermeier, A., Pang, Z.P., Kokubu, Y., S€udhof, T.C., andWer-
nig, M. (2010). Direct conversion of fibroblasts to functional neurons by defined
factors. Nature 463, 1035–1041.
Wang, D.D., and Bordey, A. (2008). The astrocyte odyssey. Prog. Neurobiol.
86, 342–367.
Xu, R.H., Sampsell-Barron, T.L., Gu, F., Root, S., Peck, R.M., Pan, G., Yu, J.,
Antosiewicz-Bourget, J., Tian, S., Stewart, R., and Thomson, J.A. (2008).
NANOG is a direct target of TGFbeta/activin-mediated SMAD signaling in
human ESCs. Cell Stem Cell 3, 196–206.
Yang, N., Zuchero, J.B., Ahlenius, H.,Marro, S., Ng, Y.H., Vierbuchen, T., Haw-
kins, J.S., Geissler, R., Barres, B.A., and Wernig, M. (2013). Generation
of oligodendroglial cells by direct lineage conversion. Nat. Biotechnol. 31,
434–439.
Yoo, A.S., Sun, A.X., Li, L., Shcheglovitov, A., Portmann, T., Li, Y., Lee-Messer,
C., Dolmetsch, R.E., Tsien, R.W., and Crabtree, G.R. (2011). MicroRNA-medi-
ated conversion of human fibroblasts to neurons. Nature 476, 228–231.
Zhang, L., Yin, J.C., Yeh, H., Ma, N.X., Lee, G., Chen, X.A., Wang, Y., Lin, L.,
Chen, L., Jin, P., et al. (2015). Small molecules efficiently reprogram human
astroglial cells into functional neurons. Cell Stem Cell 17, 735–747.
Zhuo, L., Sun, B., Zhang, C.L., Fine, A., Chiu, S.Y., andMessing, A. (1997). Live
astrocytes visualized by green fluorescent protein in transgenic mice. Dev.
Biol. 187, 36–42.
